Clinical Trials Browser

Phase 2 × Neoplasm Metastasis × pembrolizumab × Clear all

NCT03993353 2026-02-12

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

Phase 2 Completed

7 enrolled 14 charts

GastrointestinalHead & Neck

Pyridoxine-dependent epilepsy, Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Esophageal Neoplasms, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms

NCT02964078 2026-02-10

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Phase 2 Completed

27 enrolled 10 charts

Kidney Diseases, Kidney Neoplasms, Neoplasm Metastasis

NCT07176312 2026-02-04

ZANGEA

Phase 2 Recruiting

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT06027268 2026-02-03

ToPCourT

Phase 2 Active not recruiting

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06682806 2026-02-02

A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Phase 2 Terminated

Gastrointestinal

Esophageal Neoplasms, Neoplasm Metastasis

NCT07183319 2026-02-02

Circulating Tumor DNA Response In Urothelial Cancer

Phase 2 Recruiting

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT03082534 2026-01-28

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Recurrence

NCT04090528 2025-12-05

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Phase 2 Active not recruiting

60 enrolled 10 charts

Neoplasm Metastasis, Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT05282901 2025-11-24

PLUME

Phase 2 Active not recruiting

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT05052723 2025-11-19

Cabozantinib and Pembrolizumab in Metastatic Pancreas

Phase 2 Completed

21 enrolled 12 charts

Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT06246110 2025-11-12

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

Phase 2 Recruiting

Neoplasm Metastasis

NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Phase 2 Terminated

7 enrolled 10 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT03069378 2025-10-29

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Phase 2 Active not recruiting

41 enrolled 8 charts

Neoplasm Metastasis, Sarcoma

NCT06558799 2025-10-28

LUNAR-4

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03693014 2025-10-06

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

Phase 2 Active not recruiting

GenitourinaryThoracic

Urinary Bladder Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis

NCT05271604 2025-09-26

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT05036681 2025-09-17

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

Phase 2 Terminated

9 enrolled 8 charts

Neoplasm Metastasis, Endometrial Neoplasms

NCT06831136 2025-09-10

PANCARDINAL-2

Phase 2 Recruiting

Neoplasm Metastasis, Neoplasms

NCT05691829 2025-07-29

IRRADIATE-Lung

Phase 2 Terminated

19 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02705820 2025-06-17

SWIPE

Phase 2 Completed

48 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT04812535 2025-02-11

Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

Phase 2 Terminated

30 enrolled 41 charts

Neoplasm Metastasis

NCT03475004 2024-09-19

Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

Phase 2 Completed

53 enrolled 14 charts

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT04739618 2024-07-23

Metastatic Solid Cancer Clinical Trial

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT04713371 2024-05-09

A Phase 2 Trial for Patients With Metastatic Solid Cancer

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT03841747 2024-03-12

PELICAN

Phase 2 Withdrawn

Breast Neoplasms, Neoplasm Metastasis

NCT03260712 2023-11-03

Pembrolizumab in Biliary Tract Cancer

Phase 2 Completed

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Neoplasm Metastasis

NCT03567720 2023-06-01

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

Phase 2 Unknown

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03428802 2022-11-18

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

Phase 2 Recruiting

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT04116775 2022-06-23

Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.

Phase 2 Unknown

Neoplasm Metastasis, Prostatic Neoplasms

NCT04835402 2022-03-09

EPIC-1

Phase 2 Unknown

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT03139851 2021-09-10

CHEMOIMMUNE

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT03952325 2021-07-30

CONTESSA TRIO

Phase 2 Terminated

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms